Home » Stocks » Luminex

Luminex Corporation (LMNX)

Stock Price: $32.22 USD 0.16 (0.48%)
Updated Aug 10, 2020 1:56 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 1.49B
Revenue (ttm) 369.12M
Net Income (ttm) 11.08M
Shares Out 46.36M
EPS (ttm) 0.25
PE Ratio 128.86
Forward PE n/a
Dividend $0.36
Dividend Yield 1.12%

Stock Quote

Trading Day Aug 10, 2020
Last Price $32.22
Previous Close $32.06
Change ($) 0.16
Change (%) 0.48%
Day's Open 32.74
Day's Range 32.22 - 33.61
Day's Volume 721,658
52-Week Range 17.35 - 41.69

More Stats

Market Cap 1.49B
Enterprise Value 1.42B
Earnings Date (est) Nov 9, 2020
Ex-Dividend Date Jun 17, 2020
Shares Outstanding 46.36M
Float 39.99M
EPS (basic) 0.23
EPS (diluted) 0.25
FCF / Share 0.50
Dividend $0.36
Dividend Yield 1.12%
Earnings Yield 0.78%
FCF Yield 1.51%
Payout Ratio 156.50%
Shares Short 5.43M
Short Ratio 7.46
Short % of Float 15.43%
Beta 0.71
PE Ratio 128.86
Forward PE n/a
P/FCF Ratio 66.12
PS Ratio 4.05
PB Ratio 3.05
Revenue 369.12M
Operating Income 17.68M
Net Income 11.08M
Free Cash Flow 22.59M
Net Cash 78.16M
Net Cash / Share 1.69
Gross Margin 49.81%
Operating Margin 4.79%
Profit Margin 3.00%
FCF Margin 6.12%
ROA 1.77%
ROE 2.33%
ROIC 6.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 1
Overweight 0
Hold 2
Underweight 0
Sell 1

Analyst Consensus: Hold

Price Target

$38.33*
(18.98% upside)
Low
25.0
Current: $32.22
High
48.0
Target: 38.33
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue335316307271238227213203184142
Revenue Growth5.96%3.02%13.28%13.85%4.73%6.35%5.35%9.9%30.22%-
Gross Profit18319519918016916014414312596.38
Operating Income-12.0827.8537.1520.9932.0628.144.7722.7223.8411.25
Net Income-3.7718.2028.8913.8136.8639.047.1012.4114.475.23
Shares Outstanding44.1543.7343.1742.5842.0941.5640.8040.9341.2641.03
Earnings Per Share-0.090.410.670.320.860.930.170.300.340.12
EPS Growth--38.81%109.38%-62.79%-7.53%447.06%-43.33%-11.76%183.33%-
Dividend Per Share0.300.240.24-------
Dividend Growth25%0%--------
Operating Cash Flow13.5450.9057.4349.6857.3851.3426.9024.2838.2924.18
Capital Expenditures-16.25-21.29-14.64-13.13-18.71-17.08-18.09-9.77-9.55-11.10
Free Cash Flow-2.7129.6142.8036.5538.6834.278.8114.5228.7413.07
Cash & Equivalents59.1776.4412793.4514191.6972.4456.40102119
Total Debt17.18-----1.662.843.574.20
Net Cash / Debt41.9976.4412793.4514191.6970.7853.5698.29115
Assets544525491451403358306297283266
Liabilities78.8757.5252.6147.0434.0237.5336.4337.5131.7930.95
Book Value465468438404369320270260251235
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Luminex Corporation
Country United States
Employees 1,257
CEO Nachum Shamir

Stock Information

Ticker Symbol LMNX
Stock Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Unique Identifier NASDAQ: LMNX
IPO Date March 30, 2000

Description

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market. The company also provides MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; SYNCT data management software solutions; TDAS, an analysis program designed for development and optimization of nucleic acid assays; IDEAS, an image analysis software; and xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism. In addition, it offers MultiCode assays and products comprising HSV 1&2 assays, and other products to detect infectious agents in clinical samples; ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 assays, ARIES FLU A/B and RSV assays, ARIES group A strep assays, ARIES bordetella assays, ARIES GBS assay, and ARIES C. difficile assays; and VERIGENE test cartridges, as well as operates as an original equipment manufacturer of custom reagents and instrumentation. The company serves pharmaceutical companies, clinical laboratories, and research and medical institutions. Luminex Corporation was founded in 1995 and is based in Austin, Texas.